Triple-negative breast cancer (TNBC) is usually viewed as the most “inflamed” breast cancer subtype, so most immunotherapy trials for breast cancer, including immunosuppressive agents against PD-1 or PD-L1, such as atezolizumab, have been applied to TNBC [70]. This evidence concerns the gene PDCD1 and breast cancer.